Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00339924 · ClinicalTrials.gov registry record
Physicians' Understanding of Human Genetic Variation
A clinical trial, sponsored by National Human Genome Research Institute (NHGRI).
- Completed
- Registry status
- 1,258
- Enrollment target
NCT00339924: Completed study, sponsored by National Human Genome Research Institute (NHGRI).
NCT00339924 is a clinical trial that has completed, run by National Human Genome Research Institute (NHGRI). The registered enrollment target is 1,258 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00339924 has completed, sponsored by National Human Genome Research Institute (NHGRI).
- COMPLETED
- Registry status
- 1,258 participants
- Enrollment target
Study Summary
This study will develop a survey instrument to measure primary care physicians' knowledge of the variation in human genetics, their beliefs about biologic and genetic differences according to patients' race and ethnicity, and how that knowledge is used in their clinical decision making. Genomics research today is such that primary care physicians will be responsible for translating new genetic knowledge, drug therapies, and single and multiplex genetic testing into clinical practice. Physicians who are board certified general internists, including those who practice and teach in research and teaching hospitals in urban areas of the United States, may be eligible for this study. Participants will be recruited through invitation and information letters mailed to leaders of local chapters of physician organizations, through letters and e-mail sent to qualifying general internists in databases, and through e-mail sent to academic physicians who practice or teach medicine at medical schools that meet the inclusion criteria. The number of participants is estimated at 96 in the first phase of the study. The researchers are especially interested in general internists who provide general and preventative health care services to patients of various racial, ethnic, and ancestral backgrounds. This study will use qualitative methods-focus groups and semistructured interviews-and quantitative methods. Two pilot focus group sessions, with about eight members each, are planned for Washington, D.C. Other settings for the study are Atlanta, Detroit, Los Angeles, and Philadelphia. Those locations were selected based on population density, availability of several teaching hospitals with diverse patient populations, availability of physicians meeting the study requirements, and the need to address important regions nationwide. The focus groups will be separated by region and self-identified race-for example, one group consisting of African American internists from Atlanta and another
Primary Outcome
The objective of this study is to investigate how health professionals understand and use genomics in clinical practice including their knowledge and understanding of human genetic variation, race, and ethnicity in disease risk.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,258 participants |
| Start Date | 2005-07-11 |
| Est. Completion | 2012-04-13 |
What the finished NCT00339924 record still lists
NCT00339924 is an observational study that tracks outcomes without assigning an intervention. Its 1,258 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00339924 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00339924 about?
NCT00339924 is a clinical study titled "Physicians' Understanding of Human Genetic Variation". This study will develop a survey instrument to measure primary care physicians' knowledge of the variation in human genetics, their beliefs about biologic and genetic differences according to patients' race and ethnicity, and how that knowledge is used in their clinical decision making. Genomics re...
What is the current status of trial NCT00339924?
This trial is currently completed. The enrollment target is 1,258 participants. The study started on 2005-07-11. Estimated completion is 2012-04-13.
Who is sponsoring clinical trial NCT00339924?
This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06712316 · 1,260 participants · Phase 2
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- NCT06812273 · 1,260 participants · NA
Mediators and Moderators of Auditory Training
- NCT06931340 · 1,260 participants · Phase 3
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- NCT06119581 · 1,264 participants · Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI